CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Income Statement [Abstract]
Revenues	[1]	$ 25,661	$ 14,516
Costs and expenses:
Cost of sales	[2]	9,984	4,157
Selling, informational and administrative expenses	[2]	2,593	2,777
Research and development expenses	[2]	2,301	1,994
Acquired in-process research and development expenses	[3]	355	19
Amortization of intangible assets		835	858
Restructuring charges and certain acquisition-related costs		192	22
Other (income)/deductions––net		350	(1,004)
Income from continuing operations before provision/(benefit) for taxes on income	[4]	9,050	5,692
Provision/(benefit) for taxes on income		1,172	808
Income from continuing operations		7,879	4,885
Discontinued operations––net of tax		(9)	1
Net income before allocation to noncontrolling interests		7,870	4,886
Less: Net income attributable to noncontrolling interests		6	9
Net income attributable to Pfizer Inc. common shareholders		$ 7,864	$ 4,877
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 1.40	$ 0.87
Discontinued operations––net of tax (in dollars per share)		0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		1.40	0.87
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		1.37	0.86
Discontinued operations––net of tax (in dollars per share)		0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 1.37	$ 0.86
Weighted-average shares––basic		5,617	5,584
Weighted-average shares––diluted		5,758	5,662

[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian were reflected as discontinued operations. Prior-period financial information has been restated, as appropriate. See Note 1A.

[2] Exclusive of amortization of intangible assets.

[3] See Note 1D.

[4] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $56 million in the first quarter of 2022 and $27 million in the first quarter of 2021.